MX2009014102A - Sistema de administración transdérmica que comprende glicopirrolato para tratar sialorrea. - Google Patents

Sistema de administración transdérmica que comprende glicopirrolato para tratar sialorrea.

Info

Publication number
MX2009014102A
MX2009014102A MX2009014102A MX2009014102A MX2009014102A MX 2009014102 A MX2009014102 A MX 2009014102A MX 2009014102 A MX2009014102 A MX 2009014102A MX 2009014102 A MX2009014102 A MX 2009014102A MX 2009014102 A MX2009014102 A MX 2009014102A
Authority
MX
Mexico
Prior art keywords
patch
sialorrhea
transdermal
glycopyrrolate
delivery system
Prior art date
Application number
MX2009014102A
Other languages
English (en)
Inventor
Larry Dillaha
Original Assignee
Sciele Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciele Pharma Inc filed Critical Sciele Pharma Inc
Publication of MX2009014102A publication Critical patent/MX2009014102A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

En un aspecto, la invención incluye un método para tratamiento de la sialorrea, que comprende las pasos de identificar un paciente que padece de sialorrea y administrar una cantidad terapéuticamente efectiva de glicopirrolato al paciente empleando una ruta de de administración transdérmica En otro aspecto, la invención es un sistema de administración de fármaco transdérmica para tratar a un paciente que muestra sialorrea, incluyendo un parche transdérmico, una cantidad terapéuticamente efectiva de glicopirrolato contenida en el parche transdérmico para aliviar la sialorrea, y un portador farmacéuticamente aceptable. El parche transdérmico puede ser un parche monocapa de adhesivo con fármaco, un parche de múlticapa de adhesivo con un fármaco o un parche de tipo reservorio.
MX2009014102A 2007-06-22 2008-06-23 Sistema de administración transdérmica que comprende glicopirrolato para tratar sialorrea. MX2009014102A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94575807P 2007-06-22 2007-06-22
PCT/US2008/067908 WO2009002935A1 (en) 2007-06-22 2008-06-23 Transdermal delivery system comprising glycopyrrolate to treat sialorrhea

Publications (1)

Publication Number Publication Date
MX2009014102A true MX2009014102A (es) 2010-03-09

Family

ID=39719145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009014102A MX2009014102A (es) 2007-06-22 2008-06-23 Sistema de administración transdérmica que comprende glicopirrolato para tratar sialorrea.

Country Status (6)

Country Link
US (1) US20080317832A1 (es)
EP (1) EP2170305A1 (es)
JP (1) JP2010530902A (es)
AU (1) AU2008268465A1 (es)
MX (1) MX2009014102A (es)
WO (1) WO2009002935A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014123977A1 (en) * 2013-02-06 2014-08-14 Rohto Usa, Inc. Geranylgeranylacetone formulations
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
CN103690479B (zh) * 2013-12-04 2016-01-20 广东嘉博制药有限公司 一种格隆溴铵注射液及其制备方法
CN108348502A (zh) 2015-09-11 2018-07-31 博多尔实验仪器公司 软性抗胆碱能酯的方法和组合物
AU2016318594A1 (en) * 2015-09-11 2018-04-26 Bodor Laboratories, Inc. Methods and compositions for soft anticholinergic zwitterions
US20190099344A1 (en) * 2016-04-11 2019-04-04 Suven Life Sciences Limited Topical spray formulation of glycopyrrolate
US11759451B2 (en) 2020-09-15 2023-09-19 City University Of Hong Kong Therapeutic potential of glycopyrrolate and mexiletine for nervous system injury
CA3206833A1 (en) * 2021-02-05 2022-08-11 Sanwa Kagaku Kenkyusho Co., Ltd. Medicine comprising glycopyrronium salicylate
TW202245748A (zh) 2021-02-05 2022-12-01 日商三和化學研究所股份有限公司 包含吡咯醣･水楊酸鹽之藥品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352456A (en) * 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
WO2001008681A1 (en) * 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
CN100409847C (zh) * 1999-11-19 2008-08-13 美国爱科赛尔制药有限公司 乌头属生物碱经皮给药系统

Also Published As

Publication number Publication date
WO2009002935A1 (en) 2008-12-31
EP2170305A1 (en) 2010-04-07
AU2008268465A1 (en) 2008-12-31
US20080317832A1 (en) 2008-12-25
JP2010530902A (ja) 2010-09-16

Similar Documents

Publication Publication Date Title
MX2009014102A (es) Sistema de administración transdérmica que comprende glicopirrolato para tratar sialorrea.
MX2009005339A (es) Suspensiones analgesicas de liberacion modificada.
PH12015501169A1 (en) Transdermal delivery system
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
MX2009005341A (es) Sistema terapeutico transdermico para administrar la sustancia activa buprenorfina.
CY1118392T1 (el) Διαταξη διαδερμικης χορηγησεως οπιουχων παρεμποδιζουσα την καταχρηση
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
MXPA06012960A (es) Administracion transdermal de ficotoxinas.
WO2007112006A3 (en) Delivery of highly lipophilic agents via medical devices
WO2007111885A3 (en) Delivery of highly lipophilic agents via medical devices
WO2009126833A3 (en) Transdermal oxygen delivery apparatus and method
SG184244A1 (en) Medical devices including medicaments and methods of making and using same
TW200722064A (en) Delivery of highly lipophilic agents via medical devices
WO2010042471A3 (en) Medical devices for delivery of therapeutic agents to body lumens
CL2008003507A1 (es) Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
ECSP056076A (es) Sistema de suministro para droga y terapia celular
WO2009129509A3 (en) Methods and compositions for treating post-operative pain comprising a local anesthetic
MXPA06014599A (es) Uso de meloxicam en medicina veterinaria para el tratamiento de enfermedades dolorosas inflamatorias.
MX2007005065A (es) Forma de dosis de tiempo de retraso de farmacos para la terapia de insomnio.
CL2009001556A1 (es) Sistema de administración transdermica de fármacos que comprende una capa que contiene fármaco que comprende una matriz polimérica que contiene estradiol como unico fármaco; método de elaboración; útil para administrar estradiol.
MX345344B (es) Sistema terapéutico transdérmico para la administración de una sustancia activa.
MY163809A (en) Transdermal drug delivery system containing donepezil
MX2007005040A (es) Metodos y composiciones usando moduladores de pde4 para el tratamiento y manejo de lesion al sistema nervioso central.
EA201300648A1 (ru) Трансдермальная терапевтическая система (tts), содержащая ротиготин
NZ584190A (en) Once-a-day replacement transdermal administration of fentanyl

Legal Events

Date Code Title Description
FA Abandonment or withdrawal